Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir

Leuk Lymphoma. 2023 May;64(5):1054-1056. doi: 10.1080/10428194.2023.2183732. Epub 2023 Mar 13.

Authors

Tamar Tadmor¹, Guy Melamed², Tal Patalon², Hilel Alapi², Lior Rokach³

Affiliations

¹ Hematology Unit, Bnai Zion Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
² Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi tech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
³ Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

PMID: 36912366
DOI: 10.1080/10428194.2023.2183732

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents
COVID-19 Drug Treatment
COVID-19*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / complications
Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Ritonavir / adverse effects
SARS-CoV-2

Substances

nirmatrelvir
molnupiravir
Ritonavir
Antiviral Agents